What is Corvus Pharmaceuticals?
Corvus Pharmaceuticals is a clinical-stage biopharmaceutical company headquartered in Burlingame, California, dedicated to the development and commercialization of precisely targeted oncology therapies. The company's strategic focus is on creating innovative medicines for patients battling the most challenging and difficult-to-treat cancers. Corvus's approach involves rigorous scientific research and development aimed at identifying and advancing novel therapeutic candidates through clinical trials.
How much funding has Corvus Pharmaceuticals raised?
Corvus Pharmaceuticals has raised a total of $244.3M across 4 funding rounds:
Series A
$33.5M
Series B
$75M
Stock Offering
$71M
Stock Offering
$64.8M
Series A (2014): $33.5M with participation from OrbiMed
Series B (2015): $75M led by Sphera Funds Management, Jennison Associates, OrbiMed, Adams Street Partners, Rock Springs Capital, Roche, Fidelity Management and Research Company, T. Rowe Price, Novo Ventures, Cowen, Cormorant Asset Management, Blackrock, and venBio Select
Stock Issuance/Offering (2016): $71M supported by Credit Suisse and Cowen & Co.
Stock Issuance/Offering (2018): $64.8M featuring Credit Suisse and Jefferies Financial Group
Key Investors in Corvus Pharmaceuticals
OrbiMed
OrbiMed Advisors LLC is a specialized investment firm focused on the healthcare sector, with deep expertise spanning multiple therapeutic and commercial domains. The firm manages capital across biopharmaceuticals, medical devices, digital health platforms, diagnostics, and healthcare services.
Sphera Funds Management
Sphera Funds Management is a prominent hedge fund manager based in Israel, specializing in long/short equity strategies and a real estate private equity fund, employing a disciplined, fundamentals-driven investment approach.
Jennison Associates
Founded in 1969, Jennison Associates offers a range of equity and fixed income investment services across distribution channels. Jennison Associates is headquartered in New York, NY.
What's next for Corvus Pharmaceuticals?
The recent major strategic investment signals a pivotal phase for Corvus Pharmaceuticals, likely enabling the company to accelerate its clinical development programs, expand its research initiatives, and potentially scale its operations. This capital infusion is expected to support the advancement of its oncology therapies through critical stages of testing and regulatory review. The company's trajectory suggests a continued focus on innovation within the oncology space, aiming to bring impactful treatments to patients with unmet medical needs.
See full Corvus Pharmaceuticals company page
